AstraZeneca Can Overcome Recent Trial Setbacks

Dow Jones09-14 23:04

1504 GMT - AstraZeneca just suffered its third failure of a late-stage clinical trial in less than three months, but it can overcome these setbacks, Bernstein analysts say in a research note. The negative results of its Etcamah breast-cancer drug add to earlier disappointing results for its Wainua drug in a heart-disease trial and for lung-cancer drug candidate volrustomig.Swiss rival Roche was also hit by three late-stage trial failures in 2022 and its stock underperformed European peers until the fourth quarter of 2025, but AstraZeneca doesn't have to follow the same fate, Bernstein says. AstraZeneca's late-stage drug pipeline looks fuller than Roche's was back then, and the majority of its studies with results due next year should face low risk, the analysts say. AstraZeneca shares rise 3.1%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment